1. Nachman E and Verstreken P (2022) Synaptic proteostasis in Parkinson's disease. Curr Opin Neurobiol, 72: 72-79. [ DOI:10.1016/j.conb.2021.09.001] 2. Chen J, Xu J, Huang P, et al. (2022) The potential applications of traditional Chinese medicine in Parkinson's disease: A new opportunity. Biomed Pharmacother, 149: 112866. [ DOI:10.1016/j.biopha.2022.112866] 3. Bloem BR, Okun MS, Klein C (2021) Parkinson's disease. The Lancet, 397: 2284-2303. [ DOI:10.1016/S0140-6736(21)00218-X] 4. Simonet C, Schrag A, Lees AJ, Noyce AJ (2021) The motor prodromes of parkinson's disease: from bedside observation to large-scale application. J Neurol, 268: 2099-2108. [ DOI:10.1007/s00415-019-09642-0] 5. Qian H, Kang X, Hu J, et al. (2020) Reversing a model of Parkinson's disease with in situ converted nigral neurons. Nature, 582: 550-556. [ DOI:10.1038/s41586-020-2388-4] 6. Xie L and Hu L (2022) Research progress in the early diagnosis of Parkinson's disease. Neurol Sci, 43(11): 6225-6231. [ DOI:10.1007/s10072-022-06316-0] 7. Sun X, Liu F, Liu Q, et al. (2019) Quantitative research of (11)C-CFT and (18)F-FDG PET in parkinson's disease: A pilot study with NeuroQ software. Front Neurosci, 13: 299. [ DOI:10.3389/fnins.2019.00299] 8. Rebelo D, Oliveira F, Abrunhosa A, et al. (2021) A link between synaptic plasticity and reorganization of brain activity in Parkinson's disease. Proc Natl Acad Sci, USA 118. [ DOI:10.1073/pnas.2013962118] 9. de Souza AM, Pitombeira MS, de Souza LE, et al. (2021) (11)C-PK11195 plasma metabolization has the same rate in multiple sclerosis patients and healthy controls: a cross-sectional study. Neural Regen Res, 16: 2494-2498. [ DOI:10.4103/1673-5374.313062] 10. Cheon M, Kim SM, Ha SW, et al. (2022) Diagnostic Performance for Differential Diagnosis of Atypical Parkinsonian Syndromes from Parkinson's Disease Using Quantitative Indices of (18)F-FP-CIT PET/CT. Diagnostics, (Basel) 12. [ DOI:10.3390/diagnostics12061402] 11. Hsu SY, Lin HC, Chen TB, et al. (2019) Feasible classified models for parkinson disease from (99m)Tc-TRODAT-1 SPECT Imaging. Sensors (Basel), 19. [ DOI:10.3390/s19071740] 12. Rammohan N, Randall JW, Yadav P (2022) History of technological advancements towards MR-Linac: The future of image-guided radiotherapy. J Clinical Medicine, 11: 4730. [ DOI:10.3390/jcm11164730] 13. Zhao XJ, Niu XY, You HY, et al. (2019) Signal Alteration of Substantia Nigra on 3.0T Susceptibility-weighted Imaging in Parkinson's Disease and Vascular Parkinsonism. Curr Med Sci, 39: 831-835. [ DOI:10.1007/s11596-019-2113-4] 14. Zheng JH, Sun WH, Ma JJ, et al. (2022) Structural and functional abnormalities in Parkinson's disease based on voxel-based morphometry and resting-state functional magnetic resonance imaging. Neurosci Lett, 788: 136835. [ DOI:10.1016/j.neulet.2022.136835] 15. Li K, Su W, Li SH, et al. (2018) Resting state fMRI: A valuable tool for studying cognitive dysfunction in PD. Parkinsons Dis, 2018: 6278649. [ DOI:10.1155/2018/6278649] 16. Kouli A, Torsney KM, Kuan WL (2018) Parkinson's disease: Etiology, neuropathology, and pathogenesis. In: Stoker TB, Greenland JC, editors. Parkinson's Disease: Pathogenesis and Clinical Aspects. Brisbane (AU). [ DOI:10.15586/codonpublications.parkinsonsdisease.2018.ch1] 17. Terse PS, Kells AP, Noker P, et al. (2020) Safety assessment of AAV2-hGDNF administered via intracerebral injection in rats for treatment of parkinson's disease. Int J Toxicol, 1091581820966315. [ DOI:10.1177/1091581820966315] 18. Hall JM, Ehgoetz Martens KA, et al. (2016) Diffusion alterations associated with Parkinson's disease symptomatology: A review of the literature. Parkinsonism Relat Disord, 33: 12-26. [ DOI:10.1016/j.parkreldis.2016.09.026] 19. Zhang Y and Burock MA (2020) Diffusion tensor imaging in parkinson's disease and parkinsonian syndrome: A systematic review. Front Neurol, 11: 531993. [ DOI:10.3389/fneur.2020.531993] 20. Chung SJ, Cho KH, Lee YH, et al. (2021) Diffusion tensor imaging-based pontine damage as a degeneration marker in synucleinopathy. J Neurosci Res, 99: 2922-2931. [ DOI:10.1002/jnr.24926] 21. Kasa LW, Haast RAM, Kuehn TK, et al. (2021) Evaluating High Spatial Resolution Diffusion Kurtosis Imaging at 3T: Reproducibility and Quality of Fit. J Magn Reson Imaging, 53: 1175-1187. [ DOI:10.1002/jmri.27408] 22. Bai X, Zhou C, Guo T, et al. (2021) Progressive microstructural alterations in subcortical nuclei in Parkinson's disease: A diffusion magnetic resonance imaging study. Parkinsonism Relat Disord, 88: 82-89. [ DOI:10.1016/j.parkreldis.2021.06.003] 23. Bingbing G, Yujing Z, Yanwei M, et al. (2020) Diffusion Kurtosis Imaging of Microstructural Changes in Gray Matter Nucleus in Parkinson Disease. Front Neurol, 11: 252. [ DOI:10.3389/fneur.2020.00252] 24. Arab A, Wojna-Pelczar A, Khairnar A, et al. (2018) Principles of diffusion kurtosis imaging and its role in early diagnosis of neurodegenerative disorders. Brain Res Bull, 139: 91-98. [ DOI:10.1016/j.brainresbull.2018.01.015] 25. Fang Y, Dong Y, Zheng T, et al. (2017) Altered tracer distribution and clearance in the extracellular space of the substantia Nigra in a rodent model of parkinson's disease. Front Neurosci, 11: 409. [ DOI:10.3389/fnins.2017.00409] 26. Dong Y, Liu D, Zhao Y, et al. (2021) Assessment of neuroprotective effects of low-intensity transcranial ultrasound stimulation in a parkinson's disease rat model by fractional anisotropy and relaxation time T2( *) value. Front Neurosci, 15: 590354. [ DOI:10.3389/fnins.2021.590354] 27. Wei X, He S, Wang Z, et al. (2014) Fibroblast growth factor 1attenuates 6-hydroxydopamine-induced neurotoxicity: an in-vitro and in-vivo investigation in experimental models of parkinson's disease. Am J Transl Res, 6: 664-677. 28. Sy MAC and Fernandez HH (2020) Pharmacological treatment of early motor manifestations of parkinson disease (PD). Neurotherapeutics. [ DOI:10.1007/s13311-020-00924-4] 29. Ikenouchi Y, Kamagata K, Andica C, et al. (2020) Evaluation of white matter microstructure in patients with Parkinson's disease using microscopic fractional anisotropy. Neuroradiology, 62: 197-203. [ DOI:10.1007/s00234-019-02301-1] 30. Wu EX and Cheung MM (2010) MR diffusion kurtosis imaging for neural tissue characterization. NMR Biomed, 23: 836-848. [ DOI:10.1002/nbm.1506] 31. Han D, Qi L, Wu EX (2008) Extreme diffusion values for non-Gaussian diffusions. Optimization Methods and Software, 23: 703-716. [ DOI:10.1080/10556780802367171] 32. Qi L, Han D, Wu EX (2009) Principal invariants and inherent parameters of diffusion kurtosis tensors. J Mathematical Analysis and Applications, 349: 165-180. [ DOI:10.1016/j.jmaa.2008.08.049] 33. Dong Y, Yuan Y, Fang Y, et al. (2020) Effect of aquaporin 4 protein overexpression in nigrostriatal system on development of Parkinson's disease. Int J Neurosci, 1-8. [ DOI:10.1080/00207454.2020.1753727] 34. Khairnar A, Ruda-Kucerova J, Arab A, et al. (2021) Diffusion kurtosis imaging detects the time-dependent progress of pathological changes in the oral rotenone mouse model of Parkinson's disease. J Neurochem, 158: 779-797. [ DOI:10.1111/jnc.15449] 35. Zhao X, He H, Xiong X, et al. (2022) Lewy Body-Associated Proteins A-Synuclein (a-syn) as a Plasma-Based Biomarker for Parkinson's Disease. Front Aging Neurosci, 14: 869797. [ DOI:10.3389/fnagi.2022.869797] 36. Chen V and Saez-Atienzar S (2018) A tango for two: Dopamine and alpha-synuclein synergy may explain nigrostriatal degeneration in Parkinson's disease. Mov Disord, 33: 249. [ DOI:10.1002/mds.27248]
|